

# Jens Otto Lunde JÃ¸rgensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1152840/publications.pdf>

Version: 2024-02-01

298  
papers

14,140  
citations

20759

60  
h-index

30010

103  
g-index

302  
all docs

302  
docs citations

302  
times ranked

12170  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex difference in patients with controlled acromegaly—A multicentre survey. <i>Clinical Endocrinology</i> , 2023, 98, 74-81.	1.2	6
2	Should patients with adult GH deficiency receive GH replacement?. <i>European Journal of Endocrinology</i> , 2022, 186, D1-D15.	1.9	7
3	Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly. <i>EBioMedicine</i> , 2022, 75, 103763.	2.7	14
4	Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood. <i>European Journal of Endocrinology</i> , 2022, , .	1.9	4
5	The Socioeconomic Consequences of Cushing's Syndrome: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2921-e2929.	1.8	8
6	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. <i>European Journal of Endocrinology</i> , 2022, 186, P35-P52.	1.9	42
7	In utero exposure to glucocorticoids and risk of anxiety and depression in childhood or adolescence. <i>Psychoneuroendocrinology</i> , 2022, 141, 105766.	1.3	4
8	Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature. <i>Clinical Endocrinology</i> , 2021, 94, 625-635.	1.2	21
9	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1183-e1194.	1.8	48
10	Glucocorticoid use and risk of suicide: a Danish population-based case-control study. <i>World Psychiatry</i> , 2021, 20, 142-143.	4.8	8
11	$\delta^2$ -Lactoglobulin Is Insulinotropic Compared with Casein and Whey Protein Ingestion during Catabolic Conditions in Men in a Double-Blinded Randomized Crossover Trial. <i>Journal of Nutrition</i> , 2021, 151, 1462-1472.	1.3	4
12	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. <i>Endocrine Practice</i> , 2021, 27, 1216-1224.	1.1	8
13	Fibroblast Activation Protein is a GH Target: A Prospective Study of Patients with Acromegaly Before and After Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 106-115.	1.8	10
14	Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 266-275.	1.8	8
15	Growth hormone replacement in adults: Real-world data from two large studies in US and Europe. <i>Growth Hormone and IGF Research</i> , 2020, 50, 71-82.	0.5	8
16	A multidimensional cohort study of late toxicity after intensity modulated radiotherapy for sinonasal cancer. <i>Radiotherapy and Oncology</i> , 2020, 151, 58-65.	0.3	12
17	Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals. <i>Metabolism: Clinical and Experimental</i> , 2020, 105, 154188.	1.5	12
18	Increased lipolysis after infusion of acylated ghrelin: a randomized, double-blind placebo-controlled trial in hypopituitary patients. <i>Clinical Endocrinology</i> , 2020, 93, 672-677.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2â€‰%2 factorial, randomised, crossover study in human individuals. <i>Diabetologia</i> , 2020, 63, 2641-2653.	2.9	10
20	Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2975-2982.	1.8	11
21	The acute effects of growth hormone in adipose tissue is associated with suppression of antilipolytic signals. <i>Physiological Reports</i> , 2020, 8, e14373.	0.7	11
22	Phenotypic and genotypic features of a large kindred with a germline AIP variant. <i>Clinical Endocrinology</i> , 2020, 93, 146-153.	1.2	3
23	Soluble Klotho: a possible predictor of quality of life in acromegaly patients. <i>Endocrine</i> , 2020, 69, 165-174.	1.1	10
24	Growth Hormone and Obesity. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 239-250.	1.2	25
25	A model mimicking catabolic inflammatory disease; a controlled randomized study in humans. <i>PLoS ONE</i> , 2020, 15, e0241274.	1.1	4
26	No effect of 10 weeks erythropoietin treatment on lipid oxidation in healthy men. <i>Endocrine Connections</i> , 2020, 9, 1148-1155.	0.8	1
27	Insulin Resistance in Patients With Acromegaly. <i>Frontiers in Endocrinology</i> , 2019, 10, 509.	1.5	51
28	Effects of short-term prednisolone treatment on indices of lipolysis and lipase signaling in abdominal adipose tissue in healthy humans. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 1-10.	1.5	9
29	Temporal patterns of lipolytic regulators in adipose tissue after acute growth hormone exposure in human subjects: A randomized controlled crossover trial. <i>Molecular Metabolism</i> , 2019, 29, 65-75.	3.0	17
30	Unacylated Ghrelin Does Not Acutely Affect Substrate Metabolism or Insulin Sensitivity in Men With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2435-2442.	1.8	3
31	Clinical indicators of adrenal insufficiency following discontinuation of oral glucocorticoid therapy: A Danish population-based self-controlled case series analysis. <i>PLoS ONE</i> , 2019, 14, e0212259.	1.1	17
32	Prevalence of lifestyle characteristics in glucocorticoid users and non-users: a Danish population-based cross-sectional study. <i>BMJ Open</i> , 2019, 9, e030780.	0.8	6
33	Redundancy in regulation of lipid accumulation in skeletal muscle during prolonged fasting in obese men. <i>Physiological Reports</i> , 2019, 7, e14285.	0.7	10
34	Growth hormone signaling and action in obese versus lean human subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E333-E344.	1.8	12
35	Molecular adaptations in human subcutaneous adipose tissue after ten weeks of endurance exercise training in healthy males. <i>Journal of Applied Physiology</i> , 2019, 126, 569-577.	1.2	25
36	Growth hormone acts along the PPAR <sup>Î³</sup> -FSP27 axis to stimulate lipolysis in human adipocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E34-E42.	1.8	42

#	ARTICLE	IF	CITATIONS
37	Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients. <i>Hormone and Metabolic Research</i> , 2019, 51, 62-68.	0.7	14
38	Acute intravenous acyl ghrelin infusion induces thirst but does not affect sodium excretion: two randomized, double-blind, placebo-controlled crossover studies in hypopituitary patients. <i>European Journal of Endocrinology</i> , 2019, 181, 23-30.	1.9	7
39	Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. <i>European Journal of Endocrinology</i> , 2019, 181, 267-273.	1.9	51
40	Systemic, but not local, low-grade endotoxemia increases plasma sCD163 independently of the cortisol response. <i>Endocrine Connections</i> , 2019, 8, 95-99.	0.8	2
41	Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. <i>Endocrine Connections</i> , 2018, 7, R126-R134.	0.8	39
42	Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2216-2224.	1.8	59
43	THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience. <i>European Journal of Endocrinology</i> , 2018, 179, R47-R56.	1.9	43
44	Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. <i>European Journal of Endocrinology</i> , 2018, 178, 65-74.	1.9	18
45	Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study. <i>Acta Oncologica</i> , 2018, 57, 522-527.	0.8	9
46	Prolonged fasting-induced metabolic signatures in human skeletal muscle of lean and obese men. <i>PLoS ONE</i> , 2018, 13, e0200817.	1.1	22
47	Risk of cancer in patients with thyroid disease and venous thromboembolism. <i>Clinical Epidemiology</i> , 2018, Volume 10, 907-915.	1.5	3
48	Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2182-2188.	1.8	98
49	Growth hormone controls lipolysis by regulation of FSP27 expression. <i>Journal of Endocrinology</i> , 2018, 239, 289-301.	1.2	31
50	Acyl Ghrelin Induces Insulin Resistance Independently of GH, Cortisol, and Free Fatty Acids. <i>Scientific Reports</i> , 2017, 7, 42706.	1.6	34
51	Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. <i>Endocrine</i> , 2017, 56, 589-594.	1.1	6
52	Cushing's syndrome in children and adolescents: a Danish nationwide population-based cohort study. <i>European Journal of Endocrinology</i> , 2017, 176, 567-574.	1.9	12
53	Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials. <i>Growth Hormone and IGF Research</i> , 2017, 34, 38-44.	0.5	26
54	Substrate Metabolism and Insulin Sensitivity During Fasting in Obese Human Subjects: Impact of GH Blockade. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1340-1349.	1.8	22

#	ARTICLE	IF	CITATIONS
55	Systemic glucocorticoid use in Denmark: a population-based prevalence study. <i>BMJ Open</i> , 2017, 7, e015237.	0.8	40
56	No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1642-1651.	1.8	94
57	Development of ACRODAT <sup>®</sup> , a new software medical device to assess disease activity in patients with acromegaly. <i>Pituitary</i> , 2017, 20, 692-701.	1.6	51
58	Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2671-2677.	1.1	6
59	Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study. <i>European Journal of Endocrinology</i> , 2017, 176, 1-9.	1.9	91
60	Effects of Prednisolone on Serum and Tissue Fluid IGF-I Receptor Activation and Post-Receptor Signaling in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4031-4040.	1.8	16
61	Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution. <i>Clinical Epidemiology</i> , 2017, Volume 9, 591-600.	1.5	3
62	DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R247-R253.	1.9	21
63	Differential regulation of lipid and protein metabolism in obese vs. lean subjects before and after a 72-h fast. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 311, E224-E235.	1.8	38
64	Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3716-3723.	1.8	9
65	Stress hormone release is a key component of the metabolic response to lipopolysaccharide: studies in hypopituitary and healthy subjects. <i>European Journal of Endocrinology</i> , 2016, 175, 455-465.	1.9	6
66	Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo. <i>Lipids in Health and Disease</i> , 2016, 15, 160.	1.2	5
67	Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. <i>European Journal of Endocrinology</i> , 2016, 175, 181-190.	1.9	148
68	Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes. <i>Clinical Endocrinology</i> , 2016, 85, 202-206.	1.2	9
69	Glucose and Fat Metabolism in Acromegaly: From Mice Models to Patient Care. <i>Neuroendocrinology</i> , 2016, 103, 96-105.	1.2	27
70	Amino acid supplementation is anabolic during the acute phase of endotoxin-induced inflammation: A human randomized crossover trial. <i>Clinical Nutrition</i> , 2016, 35, 322-330.	2.3	40
71	Hormone and Cytokine Responses to Repeated Endotoxin Exposures—No Evidence of Endotoxin Tolerance After 5 Weeks in Humans. <i>Shock</i> , 2015, 44, 32-35.	1.0	14
72	Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men. <i>Prostate</i> , 2015, 75, 1255-1263.	1.2	63

#	ARTICLE	IF	CITATIONS
73	Serum Proteomic Changes after Randomized Prolonged Erythropoietin Treatment and/or Endurance Training: Detection of Novel Biomarkers. <i>PLoS ONE</i> , 2015, 10, e0117119.	1.1	6
74	Hyponatremia and mortality risk: a Danish cohort study of 279 508 acutely hospitalized patients. <i>European Journal of Endocrinology</i> , 2015, 173, 71-81.	1.9	118
75	GH signaling in human adipose and muscle tissue during "fast and famine": amplification of exercise stimulation following fasting compared to glucose administration. <i>European Journal of Endocrinology</i> , 2015, 173, 283-290.	1.9	16
76	Physical exercise increases autophagic signaling through ULK1 in human skeletal muscle. <i>Journal of Applied Physiology</i> , 2015, 118, 971-979.	1.2	87
77	Circulating acylghrelin levels are suppressed by insulin and increase in response to hypoglycemia in healthy adult volunteers. <i>European Journal of Endocrinology</i> , 2015, 172, 357-362.	1.9	22
78	Intact Pituitary Function is Decisive for the Catabolic Response to TNF- $\alpha$ : Studies of Protein, Glucose and Fatty Acid Metabolism in Hypopituitary and Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 578-586.	1.8	6
79	The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. <i>Growth Hormone and IGF Research</i> , 2015, 25, 174-181.	0.5	17
80	Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2171-2180.	1.8	304
81	Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. <i>European Journal of Endocrinology</i> , 2015, 173, 269-273.	1.9	23
82	Prolonged erythropoietin treatment does not impact gene expression in human skeletal muscle. <i>Muscle and Nerve</i> , 2015, 51, 554-561.	1.0	8
83	Giant prolactinoma presenting as a skull base tumor with erosion of the cervical vertebrae: pronounced responsiveness to dopamine agonist treatment. <i>British Journal of Neurosurgery</i> , 2015, 29, 87-89.	0.4	1
84	An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 140105.	0.2	9
85	Response to the Letter by Lindholm, et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L66-L67.	1.8	0
86	Fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling. <i>PLoS ONE</i> , 2014, 9, e102031.	1.1	59
87	Acromegaly according to the Danish National Registry of Patients: how valid are ICD diagnoses and how do patterns of registration affect the accuracy of registry data?. <i>Clinical Epidemiology</i> , 2014, 6, 295.	1.5	19
88	Growth Hormone Signaling in Muscle and Adipose Tissue of Obese Human Subjects: Associations With Measures of Body Composition and Interaction With Resveratrol Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2565-E2573.	1.8	15
89	Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3644-3652.	1.8	103
90	Sustained AS160 and TBC1D1 phosphorylations in human skeletal muscle 30 min after a single bout of exercise. <i>Journal of Applied Physiology</i> , 2014, 117, 289-296.	1.2	28

#	ARTICLE	IF	CITATIONS
91	Validity of the International Classification of Diseases, 10th revision discharge diagnosis codes for hyponatraemia in the Danish National Registry of Patients. <i>BMJ Open</i> , 2014, 4, e004956.	0.8	17
92	Ten weeks of aerobic training does not result in persistent changes in VLDL triglyceride turnover or oxidation in healthy men. <i>European Journal of Endocrinology</i> , 2014, 171, 603-613.	1.9	8
93	Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. <i>Acta Physiologica</i> , 2014, 210, 392-402.	1.8	34
94	Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. <i>European Journal of Endocrinology</i> , 2014, 170, 39-48.	1.9	22
95	Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. <i>European Journal of Endocrinology</i> , 2014, 170, 229-236.	1.9	65
96	Prolactinoma-associated headache and dopamine agonist treatment. <i>Cephalalgia</i> , 2014, 34, 493-502.	1.8	31
97	Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. <i>Journal of Molecular Endocrinology</i> , 2014, 52, R199-R222.	1.1	282
98	GH signaling in skeletal muscle and adipose tissue in healthy human subjects: impact of gender and age. <i>European Journal of Endocrinology</i> , 2014, 171, 623-631.	1.9	8
99	Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. <i>Clinical Endocrinology</i> , 2014, 80, 92-100.	1.2	13
100	Kinetics and utilization of lipid sources during acute exercise and acipimox. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E199-E208.	1.8	17
101	Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men. <i>Journal of Functional Foods</i> , 2014, 6, 305-310.	1.6	26
102	Acute presentation of craniopharyngioma in children and adults in a Danish national cohort. <i>Pituitary</i> , 2013, 16, 528-535.	1.6	23
103	Resveratrol in metabolic health: an overview of the current evidence and perspectives. <i>Annals of the New York Academy of Sciences</i> , 2013, 1290, 74-82.	1.8	85
104	High-Dose Resveratrol Supplementation in Obese Men. <i>Diabetes</i> , 2013, 62, 1186-1195.	0.3	402
105	Simultaneous determination of $\beta^2$ -hydroxybutyrate and $\beta^2$ -hydroxy- $\beta^2$ -methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry. <i>Clinical Biochemistry</i> , 2013, 46, 1877-1883.	0.8	35
106	Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2277-2284.	1.8	324
107	Direct Effects of Locally Administered Lipopolysaccharide on Glucose, Lipid, and Protein Metabolism in the Placebo-Controlled, Bilaterally Infused Human Leg. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2090-2099.	1.8	17
108	Use of Glucocorticoids and Risk of Venous Thromboembolism. <i>JAMA Internal Medicine</i> , 2013, 173, 743.	2.6	349

#	ARTICLE	IF	CITATIONS
109	Ghrelin- and GH-induced insulin resistance: no association with retinol-binding protein-4. <i>Endocrine Connections</i> , 2013, 2, 96-103.	0.8	4
110	Acute peripheral tissue effects of ghrelin on interstitial levels of glucose, glycerol, and lactate: a microdialysis study in healthy human subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E1273-E1280.	1.8	23
111	Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: a randomized placebo controlled trial. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E879-E889.	1.8	28
112	Direct Effects of TNF- $\alpha$ on Local Fuel Metabolism and Cytokine Levels in the Placebo-Controlled, Bilaterally Infused Human Leg. <i>Diabetes</i> , 2013, 62, 4023-4029.	0.3	43
113	Gene expression in skeletal muscle after an acute intravenous GH bolus in human subjects: identification of a mechanism regulating ANGPTL4. <i>Journal of Lipid Research</i> , 2013, 54, 1988-1997.	2.0	22
114	Reduced mRNA and Protein Expression of Perilipin A and G0/G1 Switch Gene 2 (GOS2) in Human Adipose Tissue in Poorly Controlled Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1348-E1352.	1.8	27
115	Fat Content in Liver and Skeletal Muscle Changes in a Reciprocal Manner in Patients with Acromegaly during Combination Therapy with a Somatostatin Analog and a GH Receptor Antagonist: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1227-1235.	1.8	44
116	Heart Valve Disease among Patients with Hyperprolactinemia: A Nationwide Population-Based Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1629-1634.	1.8	15
117	Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men. <i>Journal of Applied Physiology</i> , 2012, 112, 1114-1121.	1.2	17
118	Local administration of growth hormone stimulates tendon collagen synthesis in elderly men. <i>Journal of Applied Physiology</i> , 2012, 113, 1432-1438.	1.2	21
119	Mortality in Cushing's syndrome: A systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2012, 23, 278-282.	1.0	127
120	Evaluation of Functional Erythropoietin Receptor Status in Skeletal Muscle In Vivo: Acute and Prolonged Studies in Healthy Human Subjects. <i>PLoS ONE</i> , 2012, 7, e31857.	1.1	14
121	Insulin and GH Signaling in Human Skeletal Muscle In Vivo following Exogenous GH Exposure: Impact of an Oral Glucose Load. <i>PLoS ONE</i> , 2011, 6, e19392.	1.1	25
122	Novel serum biomarkers for erythropoietin use in humans: a proteomic approach. <i>Journal of Applied Physiology</i> , 2011, 110, 149-156.	1.2	24
123	Time-course effects of physiological free fatty acid surges on insulin sensitivity in humans. <i>Acta Physiologica</i> , 2011, 201, 349-356.	1.8	15
124	Incidence of craniopharyngioma in Denmark (n=189) and estimated world incidence of craniopharyngioma in children and adults. <i>Journal of Neuro-Oncology</i> , 2011, 104, 755-763.	1.4	126
125	Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects. <i>Proteomics</i> , 2011, 11, 3565-3571.	1.3	13
126	Acute Peripheral Metabolic Effects of Intraarterial Leg Infusion of Somatostatin in Healthy Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2581-2589.	1.8	7



#	ARTICLE	IF	CITATIONS
127	Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2405-2413.	1.8	56
128	Identification of New Biomarkers of Low-Dose GH Replacement Therapy in GH-Deficient Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2089-2097.	1.8	20
129	Fasting, But Not Exercise, Increases Adipose Triglyceride Lipase (ATGL) Protein and Reduces G(0)/G(1) Switch Gene 2 (GOS2) Protein and mRNA Content in Human Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1293-E1297.	1.8	68
130	Acute Peripheral Metabolic Effects of Intraarterial Ghrelin Infusion in Healthy Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 468-477.	1.8	36
131	Growth Hormone (GH)-Induced Insulin Resistance Is Rapidly Reversible: An Experimental Study in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2548-2557.	1.8	43
132	Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: a randomized trial. <i>European Journal of Endocrinology</i> , 2011, 165, 293-300.	1.9	23
133	Hypothesis: Extra-hepatic acromegaly: a new paradigm?. <i>European Journal of Endocrinology</i> , 2011, 164, 11-16.	1.9	55
134	Growth Hormone Treatment in Adults with Adult-Onset Growth Hormone Deficiency Increases Iliac Crest Trabecular Bone Turnover: A 1-Year, Double-Blind, Randomized, Placebo-Controlled Study. <i>Journal of Bone and Mineral Research</i> , 2010, 15, 293-300.	3.1	31
135	Effects of GH in human muscle and fat. <i>Pediatric Nephrology</i> , 2010, 25, 705-709.	0.9	22
136	Epidemiology of Cushing's Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 1-5.	1.2	174
137	Decreased Lipid Intermediate Levels and Lipid Oxidation Rates Despite Normal Lipolysis in Patients with Hypothyroidism. <i>Thyroid</i> , 2010, 20, 843-849.	2.4	19
138	Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. <i>European Journal of Endocrinology</i> , 2010, 163, 717-726.	1.9	38
139	Reduced Expression of Uncoupling Protein 2 in Adipose Tissue in Patients with Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3537-3541.	1.8	8
140	Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 43-51.	1.8	198
141	Exercise and Fasting Activate Growth Hormone-Dependent Myocellular Signal Transducer and Activator of Transcription-5b Phosphorylation and Insulin-Like Growth Factor-I Messenger Ribonucleic Acid Expression in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E64-E68.	1.8	25
142	Impact of Fasting on Growth Hormone Signaling and Action in Muscle and Fat. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 965-972.	1.8	36
143	Free Fatty Acids Inhibit Growth Hormone/Signal Transducer and Activator of Transcription-5 Signaling in Human Muscle: A Potential Feedback Mechanism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2204-2207.	1.8	21
144	Impact of Growth Hormone Receptor Blockade on Substrate Metabolism during Fasting in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4524-4532.	1.8	37

#	ARTICLE	IF	CITATIONS
145	Peroxisome proliferator-activated receptor $\beta$ (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults. <i>Clinical Endocrinology</i> , 2009, 71, 363-368.	1.2	5
146	Impact of GH substitution on exercise capacity and muscle strength in GH-deficient adults: a meta-analysis of blinded, placebo-controlled trials. <i>Clinical Endocrinology</i> , 2009, 71, 860-866.	1.2	27
147	Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects. <i>Endocrine Reviews</i> , 2009, 30, 152-177.	8.9	804
148	Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. <i>Clinical Endocrinology</i> , 2008, 69, 452-461.	1.2	8
149	Dose-response effects of free fatty acids on amino acid metabolism and ureagenesis. <i>Acta Physiologica</i> , 2008, 192, 369-379.	1.8	20
150	Acute Effects of Ghrelin Administration on Glucose and Lipid Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 438-444.	1.8	79
151	Ghrelin Infusion in Humans Induces Acute Insulin Resistance and Lipolysis Independent of Growth Hormone Signaling. <i>Diabetes</i> , 2008, 57, 3205-3210.	0.3	138
152	Lack of Observed Association between High Plasma Osteoprotegerin Concentrations and Ischemic Stroke Risk in a Healthy Population. <i>Clinical Chemistry</i> , 2008, 54, 1969-1974.	1.5	19
153	Growth Hormone Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background, and Growth Hormone Receptor Blockade. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2842-2850.	1.8	58
154	Serum Ghrelin Levels Are Increased in Hypothyroid Patients and Become Normalized by l-Thyroxine Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2277-2280.	1.8	36
155	Increased Protein Turnover and Proteolysis Is an Early and Primary Feature of Short-Term Experimental Hyperthyroidism in Healthy Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3999-4005.	1.8	19
156	The management of adult growth hormone deficiency syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2435-2450.	0.9	12
157	Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E920-E927.	1.8	84
158	Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1829-E1836.	1.8	87
159	Cardiovascular effects of intravenous ghrelin infusion in healthy young men. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3020-H3026.	1.5	24
160	The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1724-1728.	1.8	94
161	Effects of Cortisol on Carbohydrate, Lipid, and Protein Metabolism: Studies of Acute Cortisol Withdrawal in Adrenocortical Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3553-3559.	1.8	131
162	Detection of growth hormone abuse in sport. <i>Growth Hormone and IGF Research</i> , 2007, 17, 220-226.	0.5	134

#	ARTICLE	IF	CITATIONS
163	Assessment of hydration by means of bioelectrical impedance and arm muscle area during growth hormone (GH) replacement therapy: A prospective study of 130 GH-deficient patients. <i>Growth Hormone and IGF Research</i> , 2007, 17, 227-233.	0.5	2
164	Concomitant, specific determination of growth hormone and pegvisomant in human serum. <i>Growth Hormone and IGF Research</i> , 2007, 17, 431-434.	0.5	14
165	Effects of Growth Hormone on Glucose and Fat Metabolism in Human Subjects. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 75-87.	1.2	63
166	Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. <i>Clinical Endocrinology</i> , 2007, 66, 426-433.	1.2	27
167	Effects of free fatty acids, growth hormone and growth hormone receptor blockade on serum ghrelin levels in humans. <i>Clinical Endocrinology</i> , 2007, 66, 641-645.	1.2	26
168	Role of ghrelin in growth hormone-deficient patients. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 343-351.	1.2	0
169	A Simple Twist of Science: the Convoluting Tale of Ghrelin Continues. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3279-3280.	1.8	4
170	Serum ghrelin levels are suppressed in hypopituitary patients following insulin-induced hypoglycaemia irrespective of GH status. <i>Clinical Endocrinology</i> , 2006, 65, 210-214.	1.2	10
171	Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. <i>Journal of Internal Medicine</i> , 2006, 260, 11-21.	2.7	72
172	Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1093-1098.	1.8	50
173	GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E899-E905.	1.8	73
174	Incidence of GH deficiency – a nationwide study. <i>European Journal of Endocrinology</i> , 2006, 155, 61-71.	1.9	94
175	Free fatty acids decrease circulating ghrelin concentrations in humans. <i>European Journal of Endocrinology</i> , 2006, 154, 667-673.	1.9	41
176	Gender differences in growth hormone response to exercise before and after rhGH administration and the effect of rhGH on the hormone profile of fit normal adults. <i>Clinical Endocrinology</i> , 2005, 62, 315-322.	1.2	38
177	Hyperthyroidism and cation pumps in human skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E1265-E1269.	1.8	24
178	Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E194-E199.	1.8	57
179	Whole body and forearm substrate metabolism in hyperthyroidism: evidence of increased basal muscle protein breakdown. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E1067-E1073.	1.8	55
180	Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. <i>European Journal of Endocrinology</i> , 2005, 152, 719-726.	1.9	16

#	ARTICLE	IF	CITATIONS
181	Fasting Unmasks a Strong Inverse Association between Ghrelin and Cortisol in Serum: Studies in Obese and Normal-Weight Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 741-746.	1.8	134
182	Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. <i>European Journal of Endocrinology</i> , 2005, 152, 77-85.	1.9	27
183	Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5627-5631.	1.8	156
184	Insulin-Like Growth Factor (IGF) I, -II, and IGF Binding Protein-3 and Risk of Ischemic Stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5937-5941.	1.8	156
185	Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis. <i>European Journal of Endocrinology</i> , 2005, 153, 545-549.	1.9	22
186	Sex Steroids and the Growth Hormone/Insulin-Like Growth Factor-I Axis in Adults. <i>Hormone Research in Paediatrics</i> , 2005, 64, 37-40.	0.8	21
187	Clinical Aspects of Growth Hormone Deficiency in Adults. , 2005, 33, 1-20.		5
188	Thyroid hormone increases mannan-binding lectin levels. <i>European Journal of Endocrinology</i> , 2005, 153, 643-649.	1.9	22
189	The effect of submaximal exercise on immuno- and bioassayable IGF-I activity in patients with GH-deficiency and healthy subjects. <i>Growth Hormone and IGF Research</i> , 2005, 15, 283-290.	0.5	21
190	Acute exposure to GH during exercise stimulates the turnover of free fatty acids in GH-deficient men. <i>Journal of Applied Physiology</i> , 2004, 96, 747-753.	1.2	33
191	Growth Hormone Increases Vascular Cell Adhesion Molecule 1 Expression:in Vivoandin VitroEvidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 909-916.	1.8	21
192	Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting. <i>European Journal of Endocrinology</i> , 2004, 150, 779-787.	1.9	25
193	Expression of Leptin Receptor Isoforms and Effects of Leptin on the Proliferation and Hormonal Secretion in Human Pituitary Adenomas. <i>Hormone Research in Paediatrics</i> , 2004, 62, 129-136.	0.8	7
194	Serum Insulin-Like Growth Factor I Levels in Growth Hormone-Deficient Adults: Influence of Sex Steroids. <i>Hormone Research in Paediatrics</i> , 2004, 62, 73-76.	0.8	15
195	Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein. <i>European Journal of Endocrinology</i> , 2004, 150, 773-777.	1.9	28
196	Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters. <i>Clinical Endocrinology</i> , 2004, 60, 461-469.	1.2	12
197	Growth hormone receptor expression and function in pituitary adenomas. <i>Clinical Endocrinology</i> , 2004, 60, 576-583.	1.2	3
198	Growth Hormone and Glucose Homeostasis. <i>Hormone Research in Paediatrics</i> , 2004, 62, 51-55.	0.8	78

#	ARTICLE	IF	CITATIONS
199	The Decisive Role of Free Fatty Acids for Protein Conservation during Fasting in Humans with and without Growth Hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4371-4378.	1.8	66
200	Hyperthyroidism Is Associated with Suppressed Circulating Ghrelin Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 853-857.	1.8	90
201	Biochemical definitions of disease activity in acromegaly. <i>Growth Hormone and IGF Research</i> , 2003, 13, 98-103.	0.5	2
202	Evaluation of growth hormone stimulation tests in cured acromegalic patients. <i>Growth Hormone and IGF Research</i> , 2003, 13, 347-352.	0.5	12
203	The Effect of Growth Hormone on the Insulin-Like Growth Factor System during Fasting. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3292-3298.	1.8	30
204	Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 285, E737-E743.	1.8	36
205	Ectopic ACTH Syndrome: Discrepancy between Somatostatin Receptor Status in vivo and ex vivo, and between Immunostaining and Gene Transcription for POMC and CRH. <i>Hormone Research in Paediatrics</i> , 2002, 57, 200-204.	0.8	29
206	Circulating Levels of Ghrelin and GLP-1 are Inversely Related During Glucose Ingestion. <i>Hormone and Metabolic Research</i> , 2002, 34, 411-413.	0.7	43
207	Elevated Regional Lipolysis in Hyperthyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4747-4753.	1.8	55
208	Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4691-4698.	1.8	56
209	Body Composition and Circulating Levels of Insulin, Insulin-Like Growth Factor-Binding Protein-1 and Growth Hormone (GH)-Binding Protein Affect the Pharmacokinetics of GH in Adults Independently of Age. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2185-2193.	1.8	20
210	Plasma ghrelin levels during exercise in healthy subjects and in growth hormone-deficient patients. <i>European Journal of Endocrinology</i> , 2002, 147, 65-70.	1.9	113
211	Short-Term Growth Hormone Treatment in Girls With Turner Syndrome Decreases Fat Mass and Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. <i>Pediatrics</i> , 2002, 110, 889-896.	1.0	53
212	Somatropin and Glucose Homeostasis. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2002, 1, 229-234.	1.8	9
213	Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients. <i>Growth Hormone and IGF Research</i> , 2002, 12, 425-433.	0.5	15
214	Weight loss increases circulating levels of ghrelin in human obesity. <i>Clinical Endocrinology</i> , 2002, 56, 203-206.	1.2	393
215	Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. <i>Clinical Endocrinology</i> , 2002, 56, 159-167.	1.2	80
216	Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. <i>Clinical Endocrinology</i> , 2002, 57, 539-546.	1.2	125

#	ARTICLE	IF	CITATIONS
217	Impact of GHBP interference on estimates of GH and GH pharmacokinetics. <i>Clinical Endocrinology</i> , 2002, 57, 779-786.	1.2	38
218	Continuation of growth hormone therapy versus placebo in transition-phase patients with growth hormone deficiency: impact on body composition, insulin sensitivity, and thyroid function. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2002, 15 Suppl 5, 1355-60.	0.4	3
219	Safety aspects of growth hormone replacement in adults. <i>Growth Hormone and IGF Research</i> , 2001, 11, 59-71.	0.5	6
220	The growth hormone (GH)–insulin-like growth factor axis during testosterone replacement therapy in GH-treated hypopituitary males. <i>Growth Hormone and IGF Research</i> , 2001, 11, 104-109.	0.5	12
221	Growth hormone treatment in adults: Is there a true gender difference?. <i>Growth Hormone and IGF Research</i> , 2001, 11, S43-S48.	0.5	2
222	Growth Hormone Therapy in Adults. <i>Frontiers in Neuroendocrinology</i> , 2001, 22, 213-246.	2.5	17
223	No Influence of Prednisolone on IGFBP-3 Proteolysis in Healthy Young Men. <i>Hormone Research in Paediatrics</i> , 2001, 55, 95-101.	0.8	1
224	No Evidence of Insulin-Like Growth Factor-Binding Protein 3 Proteolysis during a Maximal Exercise Test in Elite Athletes <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 669-674.	1.8	46
225	Long-Term Effects of Continuous Subcutaneous Infusion Versus Daily Subcutaneous Injections of Growth Hormone (GH) on the Insulin-Like Growth Factor System, Insulin Sensitivity, Body Composition, and Bone and Lipoprotein Metabolism in GH-Deficient Adults <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1222-1228.	1.8	70
226	GH Strongly Affects Serum Concentrations of Mannan-Binding Lectin: Evidence for a New IGF-I Independent Immunomodulatory Effect of GH. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5383-5388.	1.8	46
227	Gene Expression of a Truncated and the Full-Length Growth Hormone (GH) Receptor in Subcutaneous Fat and Skeletal Muscle in GH-Deficient Adults: Impact of GH Treatment <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 792-796.	1.8	34
228	Continuation of Growth Hormone (GH) Substitution during Fasting in GH-Deficient Patients Decreases Urea Excretion and Conserves Protein Synthesis <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3120-3129.	1.8	31
229	No Evidence of Insulin-Like Growth Factor-Binding Protein 3 Proteolysis during a Maximal Exercise Test in Elite Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 669-674.	1.8	34
230	Gene Expression of a Truncated and the Full-Length Growth Hormone (GH) Receptor in Subcutaneous Fat and Skeletal Muscle in GH-Deficient Adults: Impact of GH Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 792-796.	1.8	29
231	Long-Term Effects of Continuous Subcutaneous Infusion Versus Daily Subcutaneous Injections of Growth Hormone (GH) on the Insulin-Like Growth Factor System, Insulin Sensitivity, Body Composition, and Bone and Lipoprotein Metabolism in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1222-1228.	1.8	58
232	Continuation of Growth Hormone (GH) Substitution during Fasting in GH-Deficient Patients Decreases Urea Excretion and Conserves Protein Synthesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3120-3129.	1.8	25
233	Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor. <i>Clinical Endocrinology</i> , 2000, 52, 181-186.	1.2	42
234	Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women. <i>Clinical Endocrinology</i> , 2000, 52, 305-312.	1.2	18

#	ARTICLE	IF	CITATIONS
235	Effects of leptin on basal and FSH stimulated steroidogenesis in human granulosa luteal cells. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 931-935.	1.3	16
236	Continuation of Growth Hormone (GH) Therapy in GH-Deficient Patients during Transition from Childhood to Adulthood: Impact on Insulin Sensitivity and Substrate Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1912-1917.	1.8	66
237	Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency. <i>Clinical Endocrinology</i> , 2000, 52, 25.	1.2	22
238	Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 124-133.	1.8	124
239	The Effect of Four Weeks of Supraphysiological Growth Hormone Administration on the Insulin-Like Growth Factor Axis in Women and Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4193-4200.	1.8	84
240	Stimulation of the 150-Kilodalton Insulin-Like Growth Factor-Binding Protein-3 Ternary Complex by Continuous and Pulsatile Patterns of Growth Hormone (GH) Administration in GH-Deficient Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4310-4314.	1.8	14
241	Growth Hormone (GH) Effects on Bone and Collagen Turnover in Healthy Adults and Its Potential as a Marker of GH Abuse in Sports: A Double Blind, Placebo-Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1505-1512.	1.8	110
242	Continuation of Growth Hormone (GH) Therapy in GH-Deficient Patients during Transition from Childhood to Adulthood: Impact on Insulin Sensitivity and Substrate Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1912-1917.	1.8	28
243	Long-term effects of growth hormone (GH) on body fluid distribution in GH deficient adults: a four months double blind placebo controlled trial. <i>European Journal of Endocrinology</i> , 1999, 140, 11-16.	1.9	25
244	Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. <i>Clinical Endocrinology</i> , 1999, 51, 309-316.	1.2	27
245	Muscle mass and function in thyrotoxic patients before and during medical treatment. <i>Clinical Endocrinology</i> , 1999, 51, 693-699.	1.2	52
246	Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults. <i>Growth Hormone and IGF Research</i> , 1999, 9, 52-60.	0.5	39
247	L-arginine-induced growth hormone secretion is not influenced by co-infusion of the nitric oxide synthase inhibitor N-monomethyl- L-arginine in healthy men. <i>Growth Hormone and IGF Research</i> , 1999, 9, 69-73.	0.5	10
248	The effect of the deterioration of insulin sensitivity on $\beta$ -cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy. <i>Growth Hormone and IGF Research</i> , 1999, 9, 96-105.	0.5	32
249	Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients. <i>Growth Hormone and IGF Research</i> , 1999, 9, 451-457.	0.5	12
250	Hepatic amino- to urea-N clearance and forearm amino-N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man. <i>Journal of Hepatology</i> , 1999, 30, 819-825.	1.8	9
251	L-Arginine and insulin-tolerance tests in the diagnosis of adult growth hormone deficiency: influence of confounding factors. <i>Clinical Endocrinology</i> , 1998, 48, 109-115.	1.2	38
252	Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects. <i>Clinical Endocrinology</i> , 1998, 48, 479-486.	1.2	48

#	ARTICLE	IF	CITATIONS
253	Growth hormone (GH) substitution for one year normalizes elevated GH-binding protein levels in GH-deficient adults secondary to a reduction in body fat. A placebo-controlled trial. <i>Growth Hormone and IGF Research</i> , 1998, 8, 105-112.	0.5	14
254	Differential effects of growth hormone and prednisolone on energy metabolism and leptin levels in humans. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 83-88.	1.5	27
255	Resting metabolic rate in healthy adults: Relation to growth hormone status and leptin levels. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 1134-1139.	1.5	45
256	Effects of Growth Hormone Replacement Therapy on IGF-Related Parameters and on the Pituitary-Gonadal Axis in GH-Deficient Males. <i>Hormone Research in Paediatrics</i> , 1998, 49, 269-278.	0.8	46
257	Increased Pulsatile, But Not Basal, Growth Hormone Secretion Rates and Plasma Insulin-Like Growth Factor I Levels during the Periovarulatory Interval in Normal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1662-1667.	1.8	105
258	Gene Transcription of Receptors for Growth Hormone-Releasing Peptide and Somatostatin in Human Pituitary Adenomas1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2997-3000.	1.8	32
259	GH stimulation tests: evaluation of GH responses to heat test versus insulin-tolerance test. <i>European Journal of Endocrinology</i> , 1998, 139, 605-610.	1.9	13
260	Different Effects of Continuous and Intermittent Patterns of Growth Hormone Administration on Lipoprotein Levels in Growth Hormone-Deficient Patients. <i>Hormone Research in Paediatrics</i> , 1998, 50, 284-291.	0.8	11
261	Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 379-381.	1.8	587
262	Gene Transcription of Receptors for Growth Hormone-Releasing Peptide and Somatostatin in Human Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2997-3000.	1.8	25
263	Metabolic Effects and Pharmacokinetics of a Growth Hormone Pulse in Healthy Adults: Relation to Age, Sex, and Body Composition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3612-3618.	1.8	75
264	Abdominal Fat Determines Growth Hormone-Binding Protein Levels in Healthy Nonobese Adults <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 123-128.	1.8	42
265	Growth Hormone. <i>Principles of Medical Biology</i> , 1997, 10, 451-466.	0.1	0
266	Hepatic amino nitrogen conversion and organ N-contents in hypothyroidism, with thyroxine replacement, and in hypothyroid rats. <i>Journal of Hepatology</i> , 1997, 26, 409-416.	1.8	8
267	Growth hormone prevents prednisolone-induced increase in functional hepatic nitrogen clearance in normal man. <i>Journal of Hepatology</i> , 1997, 27, 789-795.	1.8	28
268	Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats. <i>Hepatology</i> , 1997, 25, 964-969.	3.6	43
269	Abdominal Fat Determines Growth Hormone-Binding Protein Levels in Healthy Nonobese Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 123-128.	1.8	32
270	Effects of long-term growth hormone (GH) and triiodothyronine (T3) administration on functional hepatic nitrogen clearance in normal man. <i>Journal of Hepatology</i> , 1996, 24, 313-319.	1.8	17



#	ARTICLE	IF	CITATIONS
271	Effects of growth hormone on serum lipids and lipoproteins: Possible significance of increased peripheral conversion of thyroxine to triiodothyronine. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1016-1020.	1.5	9
272	Bioavailability of Recombinant Human Growth Hormone in Different Concentrations and Formulations. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 79, 144-149.	0.0	6
273	Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. <i>Clinical Endocrinology</i> , 1996, 45, 333-339.	1.2	18
274	Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. <i>Clinical Endocrinology</i> , 1996, 45, 681-688.	1.2	106
275	Calorigenic effects of growth hormone: the role of thyroid hormones. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 1416-1419.	1.8	29
276	Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2209-2215.	1.8	91
277	Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 3352-3359.	1.8	85
278	Body fluids, circadian blood pressure and plasma renin during growth hormone administration: a placebo-controlled study with two growth hormone doses in healthy adults. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 663-669.	0.6	26
279	Metabolic effects of growth hormone in humans. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 33-36.	1.5	76
280	Fuel metabolism in growth hormone-deficient adults. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 103-107.	1.5	17
281	Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 6-14.	1.5	17
282	Growth Hormone (GH)-Deficiency in Adults: Clinical Features and Effects of GH Substitution. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 1994, 7, 283-93.	0.4	19
283	Serum growth hormone (GH) profiles after nasally administered GH in normal subjects and GH deficient patients. <i>Clinical Endocrinology</i> , 1994, 40, 511-513.	1.2	7
284	Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 579-583.	1.5	36
285	Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: A double-blind placebo-controlled study. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 872-877.	1.5	69
286	Effects of growth hormone (GH) administration on functional hepatic nitrogen clearance: studies in normal subjects and GH-deficient patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 1220-1224.	1.8	17
287	Growth Hormone (GH) Treatment in GH-Deficient Adults; Therapeutic and Diagnostic Aspects. <i>Clinical Pediatric Endocrinology</i> , 1994, 3, 63-71.	0.4	0
288	Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. <i>Clinical Endocrinology</i> , 1993, 39, 403-408.	1.2	77

#	ARTICLE	IF	CITATIONS
289	Long-term efficacy and tolerability of octreotide treatment in acromegaly. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 44-50.	1.5	22
290	Dose-response studies on the metabolic effects of a growth hormone pulse in humans. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 172-175.	1.5	87
291	Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 728-731.	1.5	73
292	Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: Dose-response studies with biosynthetic human GH. <i>Calcified Tissue International</i> , 1991, 48, 82-87.	1.5	39
293	Long-term growth hormone treatment in growth hormone deficient adults. <i>European Journal of Endocrinology</i> , 1991, 125, 449-453.	1.9	118
294	Human Growth Hormone Replacement Therapy: Pharmacological and Clinical Aspects. <i>Endocrine Reviews</i> , 1991, 12, 189-207.	8.9	129
295	Expansion of Extracellular Volume and Suppression of Atrial Natriuretic Peptide after Growth Hormone Administration in Normal Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 768-772.	1.8	116
296	Evening versus Morning Injections of Growth Hormone (GH) in GH-Deficient Patients: Effects on 24-Hour Patterns of Circulating Hormones and Metabolites. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 207-214.	1.8	125
297	Growth hormone (GH) therapy in GH-deficient patients, the plasma Factor VIII-von Willebrand factor complex, and capillary fragility. A double-blind, placebo-controlled crossover study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1990, 50, 417-420.	0.6	15
298	Substrate metabolism during modest hyperinsulinemia in response to isolated hyperketonemia in insulin-dependent diabetic subjects. <i>Metabolism: Clinical and Experimental</i> , 1990, 39, 1309-1313.	1.5	11